Available Technologies
# of Displayed Technologies: 10 / 15
Applied Category Filter (Click To Remove): Therapeutics
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: OSU Wexner Medical Center
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: College of Pharmacy
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Medicine (COM)
- Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
A Small Molecule That Disperses Salmonella Biofilms
TS-041469 — A new compound to eliminate Salmonella biofilms to reduce typhoid fever.
The bacterium Salmonella enterica serovar Typhi (S. Typhi) is the causative agent of typhoid fever – infecting and killing an estimated 21 million and 200,000 individuals each year, respectively. Individuals contract the disease by consuming food or water contaminated with the etiologic agent …
- College: College of Medicine (COM)
- Inventors: Gunn, John; Huggins, William; Kuo, Laura; Melander, Christian
- Licensing Officer: Taysavang, Panya
Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
- Licensing Officer: Taysavang, Panya
Potential uses of IgG Fc for treating human diseases
TS-036778 —
Infectious diseases present a problem for treatment, with concerns for the overuse of antibiotic medicine, inefficiency of modern medicines, and a need in the market for novel technologies that will target and work in conjunction with the host immune system, rather than depending on external mecha…
- College: College of Medicine (COM)
- Inventors: Dai, Hongsheng; Caligiuri, Michael; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
Anti-NCL Immunoagent for Cancer Diagnosis and Therapy
TS-015251 — Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.
Despite huge advancements in detection and treatment, cancer remains a top world health concern. One of the major limitations of current technology is adequately detecting tumor margins and micrometastases. Even with aggressive tumor resection and adjuvant chemotherapy or radiotherapy, tumor cells…
- College: College of Medicine (COM)
- Inventors: Palmieri, Dario; Croce, Carlo
- Licensing Officer: Taysavang, Panya
Estrogen Receptor Beta Agonist Compounds
TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.
There is a large emphasis on the need for novel and more effective cancer therapeutics, since there were nearly 600,000 cancer deaths in the United States in 2016 alone. One method for therapy of prostate, breast, and colon cancer that has been gaining traction is the targeting of estrogen recepto…
- College: College of Pharmacy
- Inventors: Tjarks, Werner; Bartunek, Petr; Sedlak, David
- Licensing Officer: Taysavang, Panya
